Evidence map›Paper›PMID 26889479›Full record

ReviewAnnals of translational medicine2016

Toward precision medicine in Parkinson's disease.

Lu-Lu Bu, Ke Yang, Wei-Xi Xiong, Feng-Tao Liu, Boyd Anderson, Ye Wang, Jian Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Midbrain Organoids: A New Tool to Investigate Parkinson's Disease.Frontiers in cell and developmental biology · 2020
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Toward precision medicine in neurological diseases.Annals of translational medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lu-Lu Bu1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Ke Yang1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Wei-Xi Xiong1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Feng-Tao Liu1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Boyd Anderson1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Ye Wang1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Jian Wang1 Department & Institute of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China ; 2 School of Computing, National University of Singapore, Singapore.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine refers to an innovative approach selected for disease prevention and health promotion according to the individual characteristics of each patient. The goal of precision medicine is to formulate prevention and treatment strategies based on each individual with novel physiological and pathological insights into a certain disease. A multidimensional data-driven approach is about to upgrade "precision medicine" to a higher level of greater individualization in healthcare, a shift towards the treatment of individual patients rather than treating a certain disease including Parkinson's disease (PD). As one of the most common neurodegenerative diseases, PD is a lifelong chronic disease with clinical and pathophysiologic complexity, currently it is treatable but neither preventable nor curable. At its advanced stage, PD is associated with devastating chronic complications including both motor dysfunction and non-motor symptoms which impose an immense burden on the life quality of patients. Advances in computational approaches provide opportunity to establish the patient's personalized disease data at the multidimensional levels, which finally meeting the need for the current concept of precision medicine via achieving the minimal side effects and maximal benefits individually. Hence, in this review, we focus on highlighting the perspectives of precision medicine in PD based on multi-dimensional information about OMICS, molecular imaging, deep brain stimulation (DBS) and wearable sensors. Precision medicine in PD is expected to integrate the best evidence-based knowledge to individualize optimal management in future health care for those with PD.

Indexed as

deep brain stimulation (DBS)molecular imagingOMICSParkinson’s disease (PD)Precision medicinewearable sensors

Identifiers

PMID26889479
PMCPMC4731609
OpenAlexW2258605734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.